PP13. PHASE II STUDY OF THE SAFETY AND EFFICACY OF INFLIXIMAB IN GIANT CELL ARTERITIS (GCA): 22 WEEK INTERIM ANALYSIS

Background: Although GCA is responsive to glucocorticoids (GCS), therapy causes significant toxicity and often fails to induce sustained remission. Purpose: Assess safety and efficacy of infliximab (IFX) in patients (pts) with new onset GCA in a randomized, double-blind, placebo-controlled, multi-ce...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Rheumatology (Oxford, England) England), 2005-07, Vol.44 (suppl-3), p.iii18-iii18
Hauptverfasser:	Hoffman, G. S., Cid, M. C., Weyand, C. M., Stone, J. H., Rendt, K. E., Salvarani, C., Merkel, P. A., Xu, W., Visvanathan, S., Rahman, M. U.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!